(Q28552507)

4

object named as

Peter Beyer

0 references

author name string

Kiu Tay-Teo

2

0 references

Sabine Vogler

3

0 references

Stefan Wiktor

5

0 references

Kees de Joncheere

6

0 references

Suzanne Hill

Creative Commons Attribution 3.0 IGO

7

0 references

language of work or name

English

0 references

publication date

May 2016

0 references

published in

PLOS MEDICINE

0 references

volume

13

0 references

issue

5

0 references

page(s)

e1002032

0 references

copyright license

start time

31 May 2016

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted

0 references

cites work

Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Global epidemiology and genotype distribution of the hepatitis C virus infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection

19 March 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Evolving epidemiology of hepatitis C virus

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs

7 April 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

The Budget Impact of Hepatitis C Treatment in Ireland 2001-2012.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Restrictions for Medicaid Reimbursement of Sofosbuvir for the Treatment of Hepatitis C Virus Infection in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

A Budget Impact Analysis of Newly Available Hepatitis C Therapeutics and the Financial Burden on a State Correctional System

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Mixed HCV infection and reinfection in people who inject drugs--impact on therapy

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

The comparative clinical effectiveness and value of simeprevir and sofosbuvir for chronic hepatitis C virus infection

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Income level and drug related harm among people who use injection drugs in a Canadian setting

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

The price of drugs for chronic myeloid leukemia (CML) is a reflection of the unsustainable prices of cancer drugs: from the perspective of a large group of CML experts

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Discounts and rebates granted to public payers for medicines in European countries

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Hepatitis C virus clearance, reinfection, and persistence, with insights from studies of injecting drug users: towards a vaccine

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Differences in external price referencing in Europe: a descriptive overview.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Driving a decade of change: HIV/AIDS, patents and access to medicines for all.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

A lifeline to treatment: the role of Indian generic manufacturers in supplying antiretroviral medicines to developing countries

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Effectiveness of hepatitis C treatment with pegylated interferon and ribavirin in urban minority patients

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Side effects of therapy of hepatitis C and their management

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Sofosbuvir and ribavirin in HCV genotypes 2 and 3.

29 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysis

3 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4886962

Delivering affordable cancer care in high-income countries

3 June 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1002032

Disparity in market prices for hepatitis C virus direct-acting drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1002032

Mapping the availability, price, and affordability of antiepileptic drugs in 46 countries

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1002032

Cost-effectiveness versus Cost-Utility Analyses: What Are the Motives Behind Using Each and How Do Their Results Differ?-A Polish Example.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1002032

Allocating scarce financial resources for HIV treatment: benchmarking prices of antiretroviral medicines in Latin America.

21 January 2018

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1002032

Access to critical medicines: When are compulsory licenses effective in price negotiations?

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27243629

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Health Economic Data Requirements and Availability in the European Union: Results of a Survey Among 10 European Countries

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27243629